Join us for a day filled with insightful discussions, networking opportunities, and the latest advancements in cancer genetic counselling.
Don’t miss this chance to connect with experts in the field and learn about cutting-edge research that can enhance your practice.
Secure your in person or online attendance now!
This 11-month programme contains a mixture of asynchronous and synchronous material and is delivered virtually so can be completed anywhere in the world for those who wish to advance their academic and professional knowledge and skills in the area of Cancer Genetics and Genomics.
The programme is interdisciplinary and welcomes those with a minimum requirement of a degree in a relevant healthcare or biomedical subject. A strong background in basic science is encouraged, and eligible learners should be working at a senior level in a research role or healthcare discipline involving the care of patients with cancer.
This programme will lead to Certificate in Cancer Genetics and Genomics for all other learners.
For Ireland based learners, their qualification is accredited at QQI Level 9 on the National Framework of Qualification (PG25033).
Initiatives Promoting Equity, Diversity, and Inclusion in Patient Outreach Projects (IGCS Grant Recipients)
Empowered by Experience: Insights on Cancer Survivorship
Agents of Change: Patient Advocacy Organizations in Action
A Clinical Perspective: Genetics & Clinical Trial Updates
thisisGO.ie is an online personalised resource for you and yours who have been impacted by a gynaecological cancer.
Also contains: genetic pathway for those impacted by BRCA and Lynch Syndrome.
Did you know that all national clinical and non clinical trials can be found on the homepage. If your trial is not up there email contact@thisisgo.ie
Know anyone who has suffered through prostate cancer? We’re looking for the stories and voices of their support-givers. Share and register now at: https://eventbrite.ie/e/prostate-cancer-support-giver-symposium-tickets-980034027157
The benefit of EGD surveillance in individuals with Lynch syndrome is still a topic of debate.
Considering the invasive nature of the procedure, the patients’ burden, and—albeit small–the risks associated with conscious sedation and the procedure itself, it is essential to provide EGD surveillance only to individuals at high risk of developing GC and DC who could benefit from this procedure.
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(24)00073-7/fulltext#secsectitle0095
” Honestly, I now tell anyone coming to see me not to bring gifts, I just want to see you and have a laugh or two.
I discovered and concur also that the best gift someone can give is their attention and time. A casual visit or trip out for a cuppa and a chat about the ups and downs of life or gossip helps us feel like we still belong in this world.
All too often we get sidelined as if we had a contagious disease. In fact, in some ways people may see us as a walking disease rather than the person they knew before all this sickness lark happened.
https://peakd.com/health/@clodaghdowning/i-got-you-this-what-to-get-your-friend-who-has-cancer
Researchers have linked abnormal DNA methylation to several adverse outcomes, including human diseases.
So far, much of this research has been focused on cancer and tumour suppressor genes, since hypermethylation often results in the silencing of tumour suppressor genes in cancerous cells.
Compared to normal cells, the genomes in cancer cells have also been shown to be hypomethylated over all, with hypermethylation only occurring in the genes involved in tumour cell invasion, cell cycle control, DNA repair and other processes where silencing would lead to the spread of cancer.
In colon cancer, it is possible to detect hypermethylation early on in the course of disease, meaning hypermethylation may serve as a biomarker for the condition.
https://www.news-medical.net/life-sciences/What-is-DNA-Methylation.aspx
The decision regarding the multiple approaches to rectal cancer can be very challenging:
The NCCN Rectal Cancer Panel believes that a multidisciplinary approach, including representation from gastroenterology, medical oncology, surgical oncology/colorectal surgery, radiation oncology, pathology, and radiology, is necessary for treating patients with rectal cancer.
Patients with very-early-stage tumours that are T1, N0 and who meet carefully defined criteria can be managed with ESD or transanal local excision. A transabdominal resection is appropriate for other rectal lesions. A TNT approach, traditionally consisting of chemoRT/short-course RT and chemotherapy, is preferred when RT is being given.
However, ongoing clinical trials for rectal cancer are particularly focused on treatment approaches that omit surgery or RT, with the goal of improving outcomes for eligible patients. Careful surveillance is necessary to detect and manage recurrences in a prompt and effective manner.
https://jnccn.org/view/journals/jnccn/22/6/article-p366.xml
The economic case for investment in palliative care is well established, evidence-based and firmly grounded.
Due to the lack of palliative care resources, the first interaction most people will have with it is when their loved one is reaching the end of life. As a result, it is not surprising that some people believe that it only comes into play when all other treatment options have failed.
Palliative care is so much more than end-of-life. It emphasises improving the quality of life for both patients and their families by focusing on the whole person rather than only their disease.
Lynch Syndrome Ireland 